Drug intelligence / Profile preview

PF-000592379

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-000592379 is a small molecule drug developed by Pfizer as an oral treatment for pain and sexual dysfunction. It acts as a selective dopamine D3 receptor agonist. The compound was investigated for use in conditions such as erectile dysfunction and pain (including osteoarthritis of the knee), but its development has been discontinued for these indications[1][2][3]. As a new molecular entity, it belongs to the classes of analgesics and erectile dysfunction therapies[1].

Other names: 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine di(1S)-10-camphorsulfonate

Targets

DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on PF-000592379.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-000592379.

Explore the full profile